Insulin Delivery Devices Market Set to Surpass $XXB by 2031, Fueled by Tech Innovation and Rising Diabetes Burden | Novo Nordisk, GlaxoSmithKline, Eli Lilly and Company, Merck & Co., AstraZeneca, Sanofi, Roche Holding AG

Insulin Delivery devices Market is estimated to grow at a CAGR of 7.1% during the forecast period 2024-2031

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/insulin-delivery-devices-market?sg

Key Market Drivers:
• Rising Diabetes Prevalence
The global burden of diabetes is increasing significantly, particularly Type 2 diabetes. This surge is creating strong demand for effective and user-friendly insulin delivery solutions.

• Technological Advancements
Innovations such as smart insulin pens, closed-loop insulin pump systems, and Bluetooth-enabled monitoring tools are revolutionizing diabetes care, offering precision and improving glycemic control.

• Patient Preference for Minimally Invasive Devices
There is growing demand for devices that offer painless or less invasive insulin administration. Wearable and patch-based systems are gaining popularity for their convenience and comfort.

• Aging Population and Lifestyle Shifts
A rise in the elderly population and sedentary lifestyles are contributing to higher diabetes rates globally, thus increasing the need for reliable and accessible insulin delivery methods.

• Favorable Regulatory and Reimbursement Support
In developed economies, streamlined regulatory pathways and insurance coverage for advanced insulin devices are making them more accessible, which further fuels adoption.

Market Segments:
• By Product Type (Syringes, Insulin Pens, and dosers, Infusion pumps, Oral insulin, Insulin sprays, Insulin patches, Jet injectors, Automated insulin delivery system)
• By Application (Type I Diabetes, Type II Diabetes)
• By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Sales and Others)
• By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Make an Enquiry for purchasing this Report @ https://www.datamintelligence.com/enquiry/insulin-delivery-devices-market?sg

Geographical Share of the Insulin Delivery Devices Market
• North America holds a dominant share of the global insulin delivery devices market, driven by the high prevalence of diabetes, advanced healthcare infrastructure, and widespread adoption of technologically advanced insulin pumps and pens. The U.S. leads the region, with increasing demand for continuous glucose monitoring (CGM)-integrated systems.

• Europe follows closely, particularly countries like Germany, the UK, and France, which have high awareness levels and supportive reimbursement frameworks. The region is also seeing steady growth in home-use insulin devices, improving patient convenience and compliance.

• The Asia-Pacific region is the fastest-growing market, fueled by the rapidly increasing diabetic population in countries like China and India. Government initiatives to expand diabetes care access and a growing middle-class population are further boosting device adoption.

• Latin America is witnessing moderate growth, with Brazil and Mexico at the forefront. While infrastructure limitations exist, improving healthcare access and rising chronic disease burden are stimulating market expansion.

• The MEA region represents a smaller share but shows potential for future growth due to increasing awareness, improving diagnostic rates, and gradual improvements in healthcare infrastructure.

Market Key Players:
Key players are Novo Nordisk, GlaxoSmithKline, Bristol-Myers Squibb, Becton Dickinson, Eli Lilly and Company, Merck & Co., AstraZeneca, Sanofi, Roche Holding AG, Amgen, Johnson & Johnson, Abbott Laboratories and Tandem diabetes care.

DataM Intelligence Opinion:
The insulin delivery devices market is experiencing accelerated momentum, driven by an alarming rise in global diabetes prevalence particularly Type 2 diabetes combined with a push for more convenient, precise, and minimally invasive treatment methods. Technological innovation stands out as a key enabler, with smart insulin pens, automated delivery systems, and wearable devices transforming how patients manage their condition.

These advancements are not only improving glycemic control but also aligning with patient preferences for comfort and independence in chronic care management. Additionally, aging populations and sedentary lifestyles are reinforcing the demand for scalable and accessible insulin solutions across both developed and emerging economies.

Geographically, North America and Europe continue to dominate due to advanced healthcare systems, favorable reimbursement policies, and high awareness levels. However, Asia-Pacific is quickly emerging as the growth engine of the market, propelled by a soaring diabetic population, expanding healthcare access, and increased public health investment in nations like India and China.

Latin America and the Middle East & Africa are progressing steadily, although infrastructure challenges persist. At DataM Intelligence, we believe the future of this market lies in personalized, tech-integrated delivery solutions that bridge clinical accuracy with patient-centric usability particularly in regions undergoing healthcare transformation.

Stay informed with the latest industry insights-start your subscription now: https://www.datamintelligence.com/reports-subscription?sg

Mergers, Acquisitions & Corporate Moves:

Novo Nordisk expanded manufacturing capacity in late 2024 by acquiring three facilities from Novo Holdings, following the latter's acquisition of Catalent. This strategic move supports broader access to its diabetes and obesity therapies.

Medtronic announced (May 2025) that its diabetes division responsible for insulin pumps, pens, and related devices will be spun off into a standalone, publicly traded company within 18 months. This new entity, based in Northridge, California, will allow the diabetes portfolio to innovate more rapidly and decisively.

Product Launches & Approvals:

Awiqli (insulin icodec) a once-weekly insulin delivered via a prefilled FlexTouch pen-launched in Japan in January 2025. Novo Nordisk had previously secured EMA approval for this therapy in mid-2024.

Embecta's disposable tubeless patch pump, with a 300‐unit reservoir, received FDA 510(k) clearance in 2024. It is designed particularly for people with type 2 diabetes and serves as a base for future automated systems.

Sequel Med Tech and Senseonics partnered in April 2025 to launch the world's first automated insulin delivery system compatible with the Eversense 365 one‐year implantable CGM.

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.